论文部分内容阅读
目的:研究巴曲酶治疗急性脑梗塞的临床疗效、安全性,及其对血液流变学、凝血功能的影响。方法:按照单盲、随机、对照的研究方法,将68例急性脑梗塞患者随机分为治疗组33例,对照组35例。其中对照组采用常规治疗方法,治疗组在常规治疗方法的基础上加用巴曲酶治疗。观察疗效及安全性。结果:治疗组总有效率为84.85%,与对照组总有效率60%比较,差异有显著性(p<0.05)。治疗组治疗后血浆纤维蛋白原、全血粘度、血浆粘度、血小板粘附率的变化与对照组比较,差异有显著性(p<0.05)。无明显副作用。结论:急性脑梗塞使用巴曲酶治疗能提高好转率,降低患者血粘度和血纤维蛋白原浓度,安全性高。
Objective: To study the clinical efficacy and safety of batroxobin in the treatment of acute cerebral infarction and its influence on hemorheology and coagulation function. Methods: According to single-blind, randomized and controlled study, 68 patients with acute cerebral infarction were randomly divided into treatment group (33 cases) and control group (35 cases). In the control group, conventional treatment was used. The treatment group was treated with batroxobin on the basis of conventional treatment. To observe the efficacy and safety. Results: The total effective rate of the treatment group was 84.85%, which was significantly different from that of the control group (60%) (p <0.05). The changes of plasma fibrinogen, whole blood viscosity, plasma viscosity and platelet adhesion rate after treatment in the treatment group were significantly different from those in the control group (p <0.05). No obvious side effects. Conclusion: The treatment of acute cerebral infarction with batroxobin can improve the rate of improvement, reduce the blood viscosity and fibrinogen concentration, high safety.